Key Takeaways
- Goldman Sachs raised its Merck price target to $165 from $155 on Oct. 30 and kept its Buy rating. The target sits 14% above Merck’s Nov. 16 close.
- Goldman’s new target is close to the Street’s $162 average, which has risen from $102 a year ago along with the stock.
- Over the past three months, analysts have cut their 2027 earnings estimates, which now sit at about Merck’s 2025 level.
- At $165, Merck would trade at a forward multiple well above its five-year average, so the target doesn’t look too low, and the 2027 guidance in early February is the next test.
Merck (MRK) stock is up 55% over the past year, and Wall Street’s price targets have been climbing behind it. On Oct. 30, the day after Merck’s third-quarter report, Goldman Sachs analyst Asad Haider raised his target to $165 from $155 and kept his Buy rating. That puts the target 14% above the Nov. 16 close of $144.46.
Merck beat and raised in October
Merck’s third-quarter sales rose 5% to $18.1 billion, and the Keytruda family grew 6% to $8.6 billion, with $830 million of that from Keytruda Qlex, the under-the-skin version. Winrevair nearly doubled to $694 million. Management raised the midpoint of its 2026 guidance, to sales of $66.8 billion to $67.3 billion and non-GAAP EPS of $2.77 to $2.82.
But about $550 million of the quarter’s sales came from the timing of customer purchases, and Merck expects all of it to unwind in the fourth quarter and next year.
The pipeline news may matter more. Merck says sac-TMT improved median overall survival by nearly 7 months over chemotherapy in previously treated endometrial cancer, and the FDA’s decision is due by June 15, 2027. Intismeran, the personalized cancer vaccine Merck is developing with Moderna, cut the risk of melanoma recurrence or death by 42% alongside Keytruda.
Goldman’s target is right on the Street’s average
Goldman’s $165 is only 2% above the $162 consensus target. That average has climbed from $102 a year ago, in step with the stock:

The 26 targets run from $105 to $186. Barclays and Scotiabank sit at $180, while Cantor Fitzgerald holds at $155 and RBC Capital at $140.
TIKR tracks 28 analysts on Merck. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Merck, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Merck’s Analyst Ratings
Does $165 add up?
Analysts see earnings bouncing back next year, to about 2025’s level:

This year’s $2.79 is low because of one-time charges for the Cidara and Terns deals. So the comparison that matters is 2027’s $8.96 against the $8.98 Merck earned in 2025, and the 2027 figure keeps slipping: three months ago, Yahoo Finance’s consensus stood at about $9.60.
CFO Caroline Litchfield called 2027 “another year of investment,” with more than $2 billion of headwinds from generics hitting Bridion, Januvia and Adempas. Looking at 2027 consensus estimates, she said “some have incorporated the messaging that we’ve given, many have not yet.”
Meanwhile, Merck’s multiple is already well above its usual level:

Merck traded at 18x forward earnings at the Nov. 13 close, against a five-year average of 14x. Goldman’s $165 works out to 20x the same earnings.
Paying up for the pipeline
Keytruda was nearly half of Merck’s 2025 sales. Its U.S. compound patent expires in December 2028, and Merck expects Medicare’s set price for it to start in January 2029. The new drugs have to fill that hole.
So no, Goldman’s $165 isn’t too low. It already values Merck at a premium to its own history, on 2027 earnings that analysts are still cutting. After a 55% run, Merck’s 2027 guidance is the thing to see before paying more.
That guidance comes with the fourth-quarter report in early February. If it lands at or above the consensus, 20x gets a lot easier to justify.
So what is Merck stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Merck could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!